摘要
目的探究甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎的临床疗效和安全性分析。方法随机选取该院自2015年6月—2016年6月间收治的小儿难治性支原体肺炎患儿共100例作为研究对象,根据随机数表法分为对照组和观察组,每组各50例,其中对照组患儿进行常规接受阿奇霉素治疗,观察组患儿在对照组的常规治疗基础上联合甲泼尼龙治疗,连续治疗3个周期,观察并比较两组患儿的临床疗效以及不良反应。结果经治疗后,可观察到观察组患儿的总有效率96.00%明显高于对照组患儿的总有效率70.00%,差异具有统计学意义(P<0.05)。另外,观察组患儿治疗后CRP值以及住院时间、体温恢复时间分别为(13.65±5.24)mg/L、(9.25±2.35)d、(7.34±1.68)d,均明显优于对照组患儿的CRP值和住院时间、体温恢复时间,分别为(28.65±10.32)mg/L、(12.34±2.22)d、(11.25±2.34)d,差异均具有统计学意义(P<0.05),同时观察组患儿与对照组患儿均未出现不良反应。结论采用甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎具有突出疗效,不仅能够明显提高治疗效果还可以减少住院时间,且不良反应少,可在今后的临床工作中进行广泛的推广工作。
Objective This paper tries to analyze the cl inical effect of methylprednisolone and azithromycin in chi ldren with refractory mycoplasma pneumonia. Methods 100 chi ldren with refractory mycoplasma pneumonia treated from June 2015 to June 2016 in this hospi tal were random selected. The subjects were randomly divided into two groups, with 50 cases in each group. The control group took azithromycin treatment; the observation group took methylprednisolone and azithromycin treatment. After three treatment courses, the cl inical effect and adverse reactions for two groups were observed. Results Af-ter treatment, the total effective rate for the observation group was 96.00%, signif icantly higher than the control group of 70.00%, and the difference was stat is t ical ly signif icant （P〈0.05）; what ’s more, the CRP value, hospi tal ization time and re-covery time of body temperature for observation group were （13.65±5.24）mg/L,（9.25±2.35）days, （7.34±1.68）days , significantly bet ter than those in the control group of （28.65±10.32）mg/L, （12.34±2.22） days, （11.25±2.34） days, and the difference was signif icant （P〈0.05） ; no adverse reactions occurred in the two groups. Conclusion The combined therapy of methylpred- nisolone and azithromycin has an obvious effect in chi ldren with refractory mycoplasma pneumonia, which can greatly im-prove the cl inical effect, shorten the hospi tal ization time and reduce the adverse event rate. It shall be extens ively recom-mended in cl inical practice.
出处
《中外医疗》
2017年第26期120-122,共3页
China & Foreign Medical Treatment
